Development and pilot testing of a web-based decision aid for fertility-preservation decisions among women with cancer in South Korea Authors: Jeehee Han, Mina Jang, Seul Ki Kim, Jinyoung Park Published: 2026 ABSTRACT ObjectiveFertility preservation is an important concern for women of reproductive age with cancer. Many receive insufficient counseling and may experience decisional conflict and psychological distress. This study aimed to develop and pilot test SHARE, a web-based decision aid supporting fertility-preservation decisions among women of reproductive age with cancer in South Korea, using a process informed by the Ottawa Decision Support Framework and the International Patient Decision Aid Standards (IPDAS).MethodsThis development and pilot-testing study included scoping, steering-group formation, a needs assessment with 16 women who had completed cancer treatment and 7 health care professionals, evidence synthesis, iterative prototyping, think-aloud alpha testing (n = 4), and beta testing with post-treatment participants (n = 15) assessing acceptability, user experience, and the importance assigned to decision factors.ResultsSHARE comprises seven interactive modules covering fertility risks, fertility-preservation options, values clarification, and preparation for clinical discussions. Alpha testing identified navigation, terminology, personalization, and visual-design issues. In beta testing, mean module information-presentation ratings ranged from 2.73 to 3.40 on a 4-point scale; 11 of 15 participants (73.3%) reported that SHARE was useful for decision-making, and 12 of 15 (80.0%) perceived the information as balanced. User Experience Questionnaire scores were positive for Perspicuity (1.42), Efficiency (0.98), and Dependability (0.97) and neutral for Attractiveness (0.64), Stimulation (0.33), and Novelty (−0.02). The importance of starting cancer treatment as soon as possible was rated 9.67/10, compared with 6.33/10 for having a child in the future.ConclusionsThis small post-treatment pilot provided preliminary evidence of acceptability and stronger pragmatic than hedonic user-experience ratings; it did not establish decisional or clinical effectiveness. Prospective evaluation in newly diagnosed women across cancer types is warranted. Introduction The American Society of Clinical Oncology (ASCO) recognizes fertility preservation (FP) as critical in the treatment of patients of reproductive age with cancer and provides updated clinical practice guidelines.1 Accordingly, health care professionals should clearly explain infertility risks to patients and discuss FP options as early as possible, preferably before initiating cancer treatment. Nevertheless, both health care professionals and patients face decision-making challenges regarding FP. Numerous patients with cancer receive insufficient information regarding how cancer treatments affect fertility or available FP options.2 Various factors are involved, including oncologists’ limited knowledge of sexual health and fertility issues,3 scant educational resources,4 and interdisciplinary coordination difficulties within health care systems.5 Inadequate patient–clinician communication and psychological distress further complicate FP decision-making. Patients face simultaneous pressures of urgent treatment initiation, fears of fertility loss, and insufficient information,6, 7, 8 and women may experience long-term distress related to societal expectations around motherhood.9 These factors highlight the need for structured decision support that addresses informational, communication, and psychosocial dimensions within a shared decision-making (SDM) framework. Providing fertility-related information and psychosocial interventions to cancer survivors has been reported to reduce patients’ psychological distress and enhance their decision-making capacity and quality of life.10, 11, 12, 13, 14 Specifically, FP interventions improve patients' understanding of fertility issues13,14 and mitigate feelings of isolation.13 Additionally, these interventions increase patients' confidence in discussing fertility-related concerns and significantly enhance quality of life.14 Research involving couples further reported that fertility-related interventions effectively decrease cancer-related posttraumatic stress symptoms and improve relationship quality.12 However, several studies indicate potential negative effects associated with fertility-related interventions, including heightened anxiety and psychological burden among some patients.10,14 Existing research primarily examines specific cancers affecting reproductive organs, inadequately addressing the diverse effects of various cancer types and treatments on fertility.9 Ruiz et al. highlighted that most websites providing fertility-related information present difficult-to-understand content and lack information on experimental treatments or emotional support resources.15 Therefore, beyond simply providing information or enhancing coordination with health care professionals, personalized interventions tailored to individual patient needs are recommended.16 Therefore, balancing informational and psychosocial support and providing personalized interventions tailored to individual patient circumstances are crucial. Elwyn et al. emphasized the importance of SDM, a model designed to assist patients in clarifying their preferences and help health care professionals offer the best available evidence to facilitate informed patient decisions.17 This model comprises three key stages—choice talk, option talk, and decision talk—thereby promoting patient autonomy and psychological comfort. Patient decision aids and related interventions for FP have been developed across multiple countries over the past decade. Our prior integrative review of FP decision support interventions identified that existing tools have demonstrated potential to address informational gaps but have also revealed important limitations.18 Representative examples include Peate et al.'s Australian fertility-related decision aid for early-stage breast cancer,19 the U.S. Pathways website,20 the Canadian BEFORE decision aid,16 and the Australian Maybe Later Baby information resource for adolescents and young adults.10 Despite this body of work, existing tools have been developed primarily in Western contexts and in English, and have not been specifically tailored to Asian socio-cultural norms (e.g., family involvement, hierarchical clinical communication) or country-specific insurance and policy structures.21 To address these gaps in both the research base and the available decision-support tools, this study aimed to develop and pilot test a comprehensive web-based decision aid designed to support shared FP decision-making. Specifically, this study makes the following unique contributions: (1) developing a web-based platform integrating personalized information provision and psychosocial support, (2) designing a comprehensive intervention applicable to various cancer types, (3) providing structured support for subsequent patient–clinician communication, and (4) formative evaluation of usability and acceptability. This study presents practical and innovative solutions for realizing SDM in the FP field by systematizing decision-making involving both patients and health care professionals, using digital technology as an initial step beyond simple information provision. Methods Theoretical framework This study employed the Ottawa Decision Support Framework (ODSF)22 as its theoretical basis. The ODSF was selected because it operationalizes SDM through three actionable domains — decisional needs, decision support, and decisional outcomes — directly mappable to the design of an interactive decision aid. These three domains framed the SHARE program's content, modular structure, and outcome measures (Fig. 1).Fig. 1Theoretical framework of the SHARE program for supporting fertility-preservation decision-making among women of reproductive age with cancer, based on the ODSF. ODSF, Ottawa Decision Support Framework. Theoretical framework of the SHARE program for supporting fertility-preservation decision-making among women of reproductive age with cancer, based on the ODSF. ODSF, Ottawa Decision Support Framework. Development framework and scoping International patient decision aid standards systematic development process The SHARE program was systematically developed from September 2021 to June 2025, following the International Patient Decision Aid Standards (IPDAS) model for patient decision aid development.23 This framework guided our approach through six key steps: 1) scoping and defining the decision context, 2) establishing a multidisciplinary steering group, 3) assessing decisional needs and evidence synthesis, 4) iterative prototype development, 5) alpha testing with end users, and 6) beta testing (Fig. 2).Fig. 2Methodological flowchart of the six-step development and testing of the SHARE decision aid, developed using an IPDAS-informed process. FP, fertility preservation; IPDAS, International Patient Decision Aid Standards; KSFP, Korean Society for Fertility Preservation; SDM, shared decision-making. Methodological flowchart of the six-step development and testing of the SHARE decision aid, developed using an IPDAS-informed process. FP, fertility preservation; IPDAS, International Patient Decision Aid Standards; KSFP, Korean Society for Fertility Preservation; SDM, shared decision-making. Scoping The initial scoping step defined the SHARE program's specific decision context and target audience. The decision was identified as follows: “Should women of reproductive age with cancer pursue FP before initiating cancer treatment?” Target users were women of reproductive age who were newly diagnosed with cancer and facing decisions regarding FP options before gonadotoxic treatment. The scope included the FP options addressed by SHARE—embryo, oocyte, and ovarian tissue cryopreservation—together with the option not to pursue FP. Ovarian suppression with a gonadotropin-releasing hormone agonist was presented as an adjunctive option where clinically appropriate, not as a substitute for established FP methods. Key characteristics of this preference-sensitive decision included trade-offs between treatment timing and FP, variability in individual values regarding future fertility, uncertainty in success rates, and financial considerations. Establishment of steering group Expert consultations were obtained from a multidisciplinary group comprising three reproductive endocrinologists with expertise in FP, as recommended by the Korean Society for Fertility Preservation (KSFP), and three nursing faculty members, including one specializing in SDM. Consultations were sought at project initiation to refine the program's objectives and scope; additional individual feedback was obtained intermittently throughout the development process. Although not all experts participated in each step, their input helped ensure the SHARE program's clinical relevance and patient-centeredness. Decisional needs assessment Systematic literature foundation SHARE development was grounded in a comprehensive evidence synthesis examining FP decision-making needs and intervention approaches. Our integrative review18 systematically analyzed FP decision support interventions, identifying five essential attributes: detailed practical information regarding methods, risks, and costs; nondirective value clarification approaches; individualized consultations; connections to reproductive resources; and system-level reinforcement through trained personnel and referral networks. Subsequently, our mixed-methods systematic review24 examined psychosocial programs for fertility-related distress. Findings revealed that while educational interventions consistently improve fertility knowledge, psychological outcomes remain inconsistent, with patients reporting information overload and unmet emotional support needs beyond knowledge provision. These reviews highlight significant gaps in interventions tailored to the South Korean context and emphasize the need for decision aids balancing comprehensive information with emotional support. Primary implementation research Building on this evidence base, we conducted formative research to examine real-world barriers and facilitators in South Korean clinical settings. Between July 2022 and April 2024, semi-structured interviews were conducted with seven health care professionals and 16 women with a history of cancer. The health care professionals, representing various medical institutions and specialties (including medical oncology, gynecologic oncology, reproductive endocrinology, and fertility specialist nursing), were recruited via recommendations from relevant professional societies or through direct email outreach based on their extensive expertise in onco-fertility care. The 16 women, aged between 28 and 41 years (11 unmarried and 5 married), were reached and recruited through active online cancer support communities after securing administrative permission to post study advertisements. These participants of reproductive age had completed active cancer treatments and faced critical FP decisions; their cancer types were breast cancer (n = 13), lymphoma (n = 1), ovarian cancer (n = 1), and cervical cancer (n = 1), and all had undergone gonadotoxic chemotherapy. Regarding their ultimate FP decisions, most participants chose active preservation methods—such as oocyte or embryo cryopreservation and gonadotropin-releasing hormone agonist therapy—while three participants actively engaged in the SDM process but ultimately chose to opt out. Using Grol and Wensing's implementation science framework, our analysis21 identified multilevel barriers and facilitators. Patient-level barriers included insufficient basic fertility knowledge, communication difficulties, passive decision-making attitudes, and psychological burdens during cancer diagnosis. Provider barriers included insufficient FP awareness among oncology teams, time constraints limiting comprehensive discussions, and role ambiguity regarding counseling responsibilities. Key facilitators included patient knowledge and motivation, provider proactive communication, empathetic support, multidisciplinary coordination, and institutional referral systems. Key findings informing design Across the literature synthesis and primary research, patients consistently emphasized age-stratified success rates, treatment timing impact, financial costs, and long-term reproductive outcomes. Patients and providers emphasized the need for independently accessible decision support outside time-constrained consultations, the most frequently cited barrier to comprehensive counseling. These convergent findings directly informed SHARE's design: comprehensive evidence-based content addressing knowledge gaps, non-directive value clarification exercises, web-based formats for independent access, structured communication outputs, personalized modular navigation, emotionally supportive framing, and alignment with South Korean health care realities. Evidence synthesis and content development A comprehensive review of current evidence and clinical guidelines was conducted to inform the SHARE program's content development. The review incorporated authoritative sources, including ASCO clinical practice guidelines, resources from the Oncofertility Consortium, the Textbook of Fertility Preservation published by the KSFP, and recent peer-reviewed studies relevant to FP and SDM. All references informing content development were explicitly cited in the program materials, ensuring that SHARE program content was evidence-based, clinically accurate, and contextually aligned with South Korean health care practices. Format selection and distribution planning A web-based format was selected because the target population (aged 18–45) demonstrated high digital literacy, FP decisions require deliberation outside time-constrained consultations, and web-based platforms enable personalized interactive features and broader accessibility. SHARE is designed for independent patient use after cancer diagnosis but before final treatment decisions. Patients access the program at https://cau-cancer.nineonelabs.co.kr/, completing it within 30–60 minutes with save-and-return capability. Upon completion, patients generate a personalized summary report to facilitate subsequent consultations with their health care teams. Initial design During the initial design of the intervention, we developed a detailed storyboard to conceptualize the website structure and information delivery methods. Specifically, we systematically determined the content to be delivered, each page's layout, and how users would interact with the website. To ensure intuitive navigation for women of reproductive age with cancer, we structured the website to provide complex information in a stepwise manner, facilitating decision-making aligned with patients' personal preferences and values. Website development Guided by the storyboard and clinical consultations, the prototype was built in collaboration with an external development team through iterative cycles in which the research team reviewed each draft and provided feedback on user interface and user experience until the implementation aligned with the intended structure and content, consistent with human-centered design principles.25 To ensure clinical accuracy and relevance, the SHARE program content was reviewed by FP specialists from the KSFP, a nationwide professional network dedicated to FP. The advisory panel provided expert consultations regarding the overall program structure, accuracy of medical information, and appropriateness of terminology, thereby strengthening the intervention's clinical validity. Alpha testing Alpha testing participants Participants eligible for alpha testing were cancer survivors aged 18–45 years, who had previously received gonadotoxic cancer treatments and were no longer undergoing active cancer therapies (surgery, chemotherapy, or radiation therapy) at the time of enrollment. However, individuals receiving ongoing hormonal therapy remained eligible. Sex was not an eligibility criterion; all four participants, recruited directly during development, were women by self-report. Participants needed to have intact cognitive functioning, sufficient communication abilities, and no prior participation in similar intervention programs. Exclusion criteria included a history of cancer recurrence, infertility treatment before cancer diagnosis, previous hysterectomy, inability to read or comprehend survey materials (e.g., illiteracy or language barriers), and difficulty using computers or mobile devices. Four women with a history of cancer—recruited based on their expressed willingness during the development—participated in the alpha test. This formative sample size is consistent with usability-testing guidance indicating that small samples can identify most major usability problems.26 Testing procedures Alpha testing was conducted from September 30 to October 7, 2024, to evaluate initial usability and interface. A think-aloud protocol27 was applied, in which participants verbalized their thoughts in real time while interacting with the program, allowing identification of usability issues during web-based tasks. Participants were instructed to explore the prototype website and explicitly verbalize their thoughts and reactions during remotely conducted testing sessions via Zoom. The researcher's intervention was minimized during the sessions, using prompts such as “Please verbalize your current thoughts” only when participants remained silent for an extended period. Following each session, additional interviews were conducted to clarify participants' verbalizations and gain deeper insight into their thought processes. One alpha-testing participant experienced technical difficulties but completed the session after receiving technical support. Alpha testing analysis Think-aloud data were audio-recorded, transcribed verbatim, and analyzed using thematic content analysis. Two researchers independently coded transcripts, identifying patterns linked to navigation issues, terminology comprehension, information needs, and user interface preferences. Program refinement Based on feedback gathered during alpha testing, we refined the intervention's overall usability and functionality. By analyzing think-aloud protocol data, several usability issues and areas for improvement in the program's usability and accessibility were identified. Based on participants' suggestions, the following modifications were implemented: 1) adding a top navigation bar to improve accessibility across multiple pages, 2) including lay definitions for medical terminology to facilitate comprehension, 3) adding more specific FP information (e.g., interpretation of anti-Müllerian hormone test results), and 4) enlarging the login button to enhance visibility and ease of use. Beta testing Beta testing participants Beta-testing participants fulfilled the same inclusion and exclusion criteria as those in the alpha test, but did not participate in the initial development or alpha testing. As in alpha testing, sex was not an eligibility criterion; all 15 participants self-reported being women in the survey. For the beta test, 15 participants were recruited through an independent professional research agency (Korea Research, https://www.hrc.co.kr/) using its online survey panel, thereby minimizing researcher influence on recruitment and responses. The research team provided the agency with the study objectives, methods, procedures, and questionnaires for online deployment. Based on panel profile information, the agency distributed the survey link via text messages and email to eligible panel members, and only those who voluntarily consented participated. Participants therefore evaluated SHARE retrospectively, drawing on their own prior FP decision, rather than at the point of decision. A pragmatic sample of 15 participants was selected for formative beta testing to identify major usability and acceptability issues; the study was not designed to estimate intervention effectiveness or provide a precise effect-size estimate.28,29 No missing data were observed as all participants completed the full program and all survey items. Testing procedures Beta testing evaluated intervention performance in a realistic usage environment and was carried out from March 1, 2025, to March 31, 2025. Immediately after completing the SHARE program, participants completed surveys assessing acceptability and user experience. Participants were informed that there were no right or wrong answers and that responses would remain anonymous to further minimize response bias. Three primary assessment tools were used. Value clarification exercise: Participants rated the importance of eight factors relevant to FP decisions from 0 (not important) to 10 (very important). The items represented distinct decision factors and were analyzed individually; no total score or internal-consistency estimate was calculated. Ratings were summarized descriptively to characterize the relative importance assigned to each factor. The tool was developed based on a literature review24 and prior empirical findings,21 including a mixed-methods systematic review and a qualitative study, which informed the relevance and content of the value-related items included in the tool. Acceptability: Program acceptability was assessed using a modified version of the Acceptability Questionnaire originally developed by O'Connor and Cranney30 and obtained from the Ottawa Hospital Research Institute's decision aid evaluation toolkit. The modified questionnaire comprised 20 acceptability components (18 closed-ended and 2 open-ended items), including seven section-specific ratings of content presentation, one item on the amount of information, one on balance of information, one on perceived usefulness, seven items assessing whether each module facilitated FP decision-making, one item on information sufficiency, and two open-ended feedback items. For each of the seven modules, participants rated information-presentation quality on a four-point scale (poor/fair/good/excellent). The amount-of-information item used the response options too much/too little/adequate, and the balance item used the options biased toward pursuing FP/biased toward not pursuing FP/balanced. The usefulness and information-sufficiency items were each rated yes/no, and the seven decision-facilitation items were each rated as having made the FP decision easier or more difficult; all three item types included a free-text ‘other’ option and an open-ended follow-up. For the decision-facilitation items, Table 4 reports the number and percentage of participants who selected ‘easier’ for each module. Because the modified questionnaire included heterogeneous item formats, exploratory internal consistency was assessed using Cronbach's alpha only for conceptually homogeneous item subsets with comparable response formats. In this pilot sample, Cronbach's α was 0.84 for the seven items rating information presentation quality per module (Table 4: “Evaluation of Information Presentation Quality per module”) and 0.87 for the seven items assessing decision facilitation per module (Table 4: “Decision-facilitation evaluation per module”; n = 14, after excluding one non-ordinal ‘other’ response). The exclusion was applied listwise: one participant selected the free-text ‘other’ option for the Module 1 decision-facilitation item and was therefore excluded from the seven-item subscale used to compute this alpha coefficient. Single-item indicators and open-ended responses were analyzed descriptively.Table 1Content of the SHARE decision aid.Table 1ModuleTitleMain content1Beginning to explore fertility preservationEmphasizing the importance of decision-making regarding fertility preservation2Understanding fertility risks from treatment•Understanding reproductive organs and pregnancy•Importance of age and ovarian function•Fertility risks from cancer treatment•Fertility risks by cancer type3Exploring fertility preservation options•Overview of available fertility preservation methods and procedures•Detailed explanation of each method (target group, cost, National Health Insurance coverage status, advantages, disadvantages)4Reviewing my current situation and future plans•Assessment of personal circumstances (cancer type, treatment status)•Review of fertility-related concerns and pregnancy plans5Clarifying my values•Evaluating personal values regarding fertility preservation•Rating important decision-making factors (future childbearing plans, focusing on cancer treatment, physical burdens, medical costs, opinions of family and health care providers)6Preparing for my fertility preservation decision•Assessing readiness to make fertility preservation decisions•Organizing personal decisions and preparing for communication with health care providers, including a list of questions7Empowering resources for decision-making•Sharing patient narratives regarding fertility preservation decisions•Providing reference websites and resources related to fertility preservation, including updates on Korea-specific national policies (e.g., government support for gamete cryopreservation prior to cancer treatment and the expansion on National Health Insurance coverage for fertility-related procedures)Table 2Beta-testing participant characteristics (N = 15).Table 2VariableCategoryMean ± SD (min, max) or n (%)Age (years)41.33 ± 3.16 (33, 45)Age at time of diagnosis (years)36.07 ± 3.91 (29, 43)Duration since diagnosis (years)5.27 ± 2.96 (1, 11)Cancer typeBreast cancerLeukemia14 (93.3)1 (6.7)Cancer stageStage IStage IIStage IIIUnknown6 (40.0)5 (33.3)3 (20.0)1 (6.7)Surgery after diagnosisYesNo14 (93.3)1 (6.7)Number of chemotherapy sessions468166 (40.0)1 (6.7)3 (20.0)5 (33.3)Radiotherapy after diagnosisYesNo12 (80.0)3 (20.0)Hormone therapy statusNoneOngoingCompleted7 (46.7)7 (46.7)1 (6.7)Marital status at the time of diagnosisMarriedDivorcedSingle11 (73.3)1 (6.7)3 (20.0)Educational levelHigh school or belowCollege or above3 (20.0)12 (80.0)Work statusUnemployedEmployeeHousewife3 (20.0)7 (46.7)5 (33.3)Initial timing of hearing fertility-related informationBefore diagnosisImmediately after diagnosisOn treatment1 (6.7)6 (40.0)8 (53.3)Initial source of fertility-related informationOncologistGynecologistGynecology nurseSupport groupsMedia or Internet Search3 (20.0)3 (20.0)1 (6.7)4 (26.7)4 (26.7)Experience of discussing fertility preservation with familyYesNo6 (40.0)9 (60.0)Experience of obstetrics and gynecology consultation before treatmentYesNo6 (40.0)9 (60.0)Fertility preservation before treatmentYesNo1 (6.7)14 (93.3)Perceived financial burden of fertility preservationNot burdensomeSomewhat burdensomeVery burdensome2 (13.3)8 (53.3)5 (33.3)SD, standard deviation; Min, minimum; Max, maximum.Table 3Participants’ values and preferences (N = 15).Table 3ItemScore, mean ± SDHaving a child in the future6.33 ± 3.66Avoiding infertility5.40 ± 3.42Focusing solely on cancer treatment9.33 ± 0.98Starting treatment as soon as possible9.67 ± 0.72Avoiding the physical burden of fertility preservation procedures7.73 ± 2.22Cost of fertility preservation8.07 ± 1.91Health care providers' opinion on fertility preservation7.87 ± 2.13Family (partner, parents) opinion on fertility preservation7.33 ± 2.61SD, standard deviation. Items were rated from 0 (not important) to 10 (very important).Table 4Ratings of the SHARE decision aid's acceptability (N = 15).Table 4ItemCategoryMean ± SD or n (%)Evaluation of informationpresentation quality per moduleModule 1: Beginning to explore FP2.73 ± 0.70Module 2: Understanding fertility risks from treatment3.00 ± 0.93Module 3: Exploring FP options3.40 ± 0.74Module 4: Reviewing my current situation and future plans2.73 ± 0.46Module 5: Clarifying my values3.33 ± 0.72Module 6: Preparing for my FP decision3.27 ± 0.70Module 7: Empowering resources for decision-making3.07 ± 1.03Perceived amount ofinformationToo much1 (6.7)Too little4 (26.7)Adequate10 (66.7)Perceived decision inclinationToward undergoing FP3 (20.0)Toward not undergoing FP0 (0.0)Balanced12 (80.0)Usefulness for decision-makingYes11 (73.3)No2 (13.3)Other2 (13.3)Decision-facilitation evaluation per moduleModule 1: Beginning to explore FP11 (73.3)Module 2: Understanding fertility risks from treatment12 (80.0)Module 3: Exploring FP options13 (86.7)Module 4: Reviewing my current situation and future plans11 (73.3)Module 5: Clarifying my values13 (86.7)Module 6: Preparing for my FP decision12 (80.0)Module 7: Empowering resources for decision-making10 (66.7)Contains sufficient information for decision-makingYes11 (73.3)No2 (13.3)Other2 (13.3)FP, fertility preservation; SD, standard deviation. Information-presentation quality was rated on a four-point scale (1 = poor, 2 = fair, 3 = good, 4 = excellent). For decision-facilitation, values represent the number and percentage of participants who reported that the module made the fertility-preservation decision easier; the remaining participants reported that the module made the decision more difficult or gave an open-ended response. Table 1Content of the SHARE decision aid.Table 1ModuleTitleMain content1Beginning to explore fertility preservationEmphasizing the importance of decision-making regarding fertility preservation2Understanding fertility risks from treatment•Understanding reproductive organs and pregnancy•Importance of age and ovarian function•Fertility risks from cancer treatment•Fertility risks by cancer type3Exploring fertility preservation options•Overview of available fertility preservation methods and procedures•Detailed explanation of each method (target group, cost, National Health Insurance coverage status, advantages, disadvantages)4Reviewing my current situation and future plans•Assessment of personal circumstances (cancer type, treatment status)•Review of fertility-related concerns and pregnancy plans5Clarifying my values•Evaluating personal values regarding fertility preservation•Rating important decision-making factors (future childbearing plans, focusing on cancer treatment, physical burdens, medical costs, opinions of family and health care providers)6Preparing for my fertility preservation decision•Assessing readiness to make fertility preservation decisions•Organizing personal decisions and preparing for communication with health care providers, including a list of questions7Empowering resources for decision-making•Sharing patient narratives regarding fertility preservation decisions•Providing reference websites and resources related to fertility preservation, including updates on Korea-specific national policies (e.g., government support for gamete cryopreservation prior to cancer treatment and the expansion on National Health Insurance coverage for fertility-related procedures) Content of the SHARE decision aid. •Understanding reproductive organs and pregnancy Understanding reproductive organs and pregnancy •Importance of age and ovarian function Importance of age and ovarian function •Fertility risks from cancer treatment Fertility risks from cancer treatment •Fertility risks by cancer type Fertility risks by cancer type •Overview of available fertility preservation methods and procedures Overview of available fertility preservation methods and procedures •Detailed explanation of each method (target group, cost, National Health Insurance coverage status, advantages, disadvantages) Detailed explanation of each method (target group, cost, National Health Insurance coverage status, advantages, disadvantages) •Assessment of personal circumstances (cancer type, treatment status) Assessment of personal circumstances (cancer type, treatment status) •Review of fertility-related concerns and pregnancy plans Review of fertility-related concerns and pregnancy plans •Evaluating personal values regarding fertility preservation Evaluating personal values regarding fertility preservation •Rating important decision-making factors (future childbearing plans, focusing on cancer treatment, physical burdens, medical costs, opinions of family and health care providers) Rating important decision-making factors (future childbearing plans, focusing on cancer treatment, physical burdens, medical costs, opinions of family and health care providers) •Assessing readiness to make fertility preservation decisions Assessing readiness to make fertility preservation decisions •Organizing personal decisions and preparing for communication with health care providers, including a list of questions Organizing personal decisions and preparing for communication with health care providers, including a list of questions •Sharing patient narratives regarding fertility preservation decisions Sharing patient narratives regarding fertility preservation decisions •Providing reference websites and resources related to fertility preservation, including updates on Korea-specific national policies (e.g., government support for gamete cryopreservation prior to cancer treatment and the expansion on National Health Insurance coverage for fertility-related procedures) Providing reference websites and resources related to fertility preservation, including updates on Korea-specific national policies (e.g., government support for gamete cryopreservation prior to cancer treatment and the expansion on National Health Insurance coverage for fertility-related procedures) Table 2Beta-testing participant characteristics (N = 15).Table 2VariableCategoryMean ± SD (min, max) or n (%)Age (years)41.33 ± 3.16 (33, 45)Age at time of diagnosis (years)36.07 ± 3.91 (29, 43)Duration since diagnosis (years)5.27 ± 2.96 (1, 11)Cancer typeBreast cancerLeukemia14 (93.3)1 (6.7)Cancer stageStage IStage IIStage IIIUnknown6 (40.0)5 (33.3)3 (20.0)1 (6.7)Surgery after diagnosisYesNo14 (93.3)1 (6.7)Number of chemotherapy sessions468166 (40.0)1 (6.7)3 (20.0)5 (33.3)Radiotherapy after diagnosisYesNo12 (80.0)3 (20.0)Hormone therapy statusNoneOngoingCompleted7 (46.7)7 (46.7)1 (6.7)Marital status at the time of diagnosisMarriedDivorcedSingle11 (73.3)1 (6.7)3 (20.0)Educational levelHigh school or belowCollege or above3 (20.0)12 (80.0)Work statusUnemployedEmployeeHousewife3 (20.0)7 (46.7)5 (33.3)Initial timing of hearing fertility-related informationBefore diagnosisImmediately after diagnosisOn treatment1 (6.7)6 (40.0)8 (53.3)Initial source of fertility-related informationOncologistGynecologistGynecology nurseSupport groupsMedia or Internet Search3 (20.0)3 (20.0)1 (6.7)4 (26.7)4 (26.7)Experience of discussing fertility preservation with familyYesNo6 (40.0)9 (60.0)Experience of obstetrics and gynecology consultation before treatmentYesNo6 (40.0)9 (60.0)Fertility preservation before treatmentYesNo1 (6.7)14 (93.3)Perceived financial burden of fertility preservationNot burdensomeSomewhat burdensomeVery burdensome2 (13.3)8 (53.3)5 (33.3)SD, standard deviation; Min, minimum; Max, maximum. Beta-testing participant characteristics (N = 15). SD, standard deviation; Min, minimum; Max, maximum. Table 3Participants’ values and preferences (N = 15).Table 3ItemScore, mean ± SDHaving a child in the future6.33 ± 3.66Avoiding infertility5.40 ± 3.42Focusing solely on cancer treatment9.33 ± 0.98Starting treatment as soon as possible9.67 ± 0.72Avoiding the physical burden of fertility preservation procedures7.73 ± 2.22Cost of fertility preservation8.07 ± 1.91Health care providers' opinion on fertility preservation7.87 ± 2.13Family (partner, parents) opinion on fertility preservation7.33 ± 2.61SD, standard deviation. Items were rated from 0 (not important) to 10 (very important). Participants’ values and preferences (N = 15). SD, standard deviation. Items were rated from 0 (not important) to 10 (very important). Table 4Ratings of the SHARE decision aid's acceptability (N = 15).Table 4ItemCategoryMean ± SD or n (%)Evaluation of informationpresentation quality per moduleModule 1: Beginning to explore FP2.73 ± 0.70Module 2: Understanding fertility risks from treatment3.00 ± 0.93Module 3: Exploring FP options3.40 ± 0.74Module 4: Reviewing my current situation and future plans2.73 ± 0.46Module 5: Clarifying my values3.33 ± 0.72Module 6: Preparing for my FP decision3.27 ± 0.70Module 7: Empowering resources for decision-making3.07 ± 1.03Perceived amount ofinformationToo much1 (6.7)Too little4 (26.7)Adequate10 (66.7)Perceived decision inclinationToward undergoing FP3 (20.0)Toward not undergoing FP0 (0.0)Balanced12 (80.0)Usefulness for decision-makingYes11 (73.3)No2 (13.3)Other2 (13.3)Decision-facilitation evaluation per moduleModule 1: Beginning to explore FP11 (73.3)Module 2: Understanding fertility risks from treatment12 (80.0)Module 3: Exploring FP options13 (86.7)Module 4: Reviewing my current situation and future plans11 (73.3)Module 5: Clarifying my values13 (86.7)Module 6: Preparing for my FP decision12 (80.0)Module 7: Empowering resources for decision-making10 (66.7)Contains sufficient information for decision-makingYes11 (73.3)No2 (13.3)Other2 (13.3)FP, fertility preservation; SD, standard deviation. Information-presentation quality was rated on a four-point scale (1 = poor, 2 = fair, 3 = good, 4 = excellent). For decision-facilitation, values represent the number and percentage of participants who reported that the module made the fertility-preservation decision easier; the remaining participants reported that the module made the decision more difficult or gave an open-ended response. Ratings of the SHARE decision aid's acceptability (N = 15). FP, fertility preservation; SD, standard deviation. Information-presentation quality was rated on a four-point scale (1 = poor, 2 = fair, 3 = good, 4 = excellent). For decision-facilitation, values represent the number and percentage of participants who reported that the module made the fertility-preservation decision easier; the remaining participants reported that the module made the decision more difficult or gave an open-ended response. Usability: The intervention website's overall usability was measured using the Korean version of the User Experience Questionnaire (UEQ),31 available from the official UEQ website.32 The UEQ comprises 26 items rated on a 7-point semantic differential scale across six domains (attractiveness, perspicuity, efficiency, dependability, stimulation, novelty). Participants completed the UEQ as a self-administered online survey immediately after using the SHARE program. UEQ scores were interpreted using the standard UEQ thresholds, in which values between −0.8 and 0.8 indicate a neutral evaluation, values above 0.8 indicate a positive evaluation, and values below −0.8 indicate a negative evaluation. To provide additional context, the observed scores were also compared with the established UEQ benchmark for web sites and web services (computed using the UEQ Data Analysis Tool, Version 12; accessed February 6, 2025). Cronbach's α coefficients for the UEQ subscales were 0.85 for attractiveness, 0.56 for perspicuity, 0.46 for efficiency, 0.56 for dependability, 0.72 for stimulation, and 0.52 for novelty. Because the UEQ Handbook (2023) notes that alpha coefficients are sensitive to sampling effects and may be unstable in small samples, these subscale reliability estimates were interpreted cautiously.32 Beta testing analysis Usability and acceptability were analyzed as indicators of decision-support performance. The value-clarification ratings described participants’ decision factors. No clinical or decisional-effectiveness outcomes were evaluated in this formative pilot study. Quantitative data were analyzed using SPSS 28.0. Descriptive statistics, including means, standard deviations, frequencies, and percentages, were used to summarize participant characteristics and outcomes. Results Design of the SHARE decision aid The SHARE decision aid was developed as a web-based program to support informed decision-making among women of reproductive age with cancer. The program architecture comprises seven interactive modules, which introduce fertility risks associated with cancer treatments, present evidence-based FP options, guide patients in reviewing their current circumstances and future plans, and offer structured value clarification activities. Subsequent sessions supported preparation for decision-making and provided empowering resources, including patient narratives and links to trustworthy websites. Interactive features—including testimonials, graphical side-by-side option comparisons, and lay definitions of medical terminology—were incorporated to enhance comprehension and engagement. Following iterative refinements, the final SHARE decision aid presented a stepwise web interface that guided users through the decision-making process. Fig. 3 illustrates the final interfaces of the SHARE program. Table 1 summarizes the program modules’ content and structure.Fig. 3Representative user interfaces of the web-based SHARE decision aid, displayed in Korean: (A) web interface home screen, showing (1) the navigation menu (fertility-preservation decision making, decision resources, and related institutions) and (2) the tagline “Supporting fertility-preservation decisions for patients with cancer”; (B) mobile interface, showing (3) the home screen with the SHARE logo and tagline and (4) the module list (Modules 3–5: exploring fertility-preservation options, reviewing my current situation and future plans, and clarifying my values). Representative user interfaces of the web-based SHARE decision aid, displayed in Korean: (A) web interface home screen, showing (1) the navigation menu (fertility-preservation decision making, decision resources, and related institutions) and (2) the tagline “Supporting fertility-preservation decisions for patients with cancer”; (B) mobile interface, showing (3) the home screen with the SHARE logo and tagline and (4) the module list (Modules 3–5: exploring fertility-preservation options, reviewing my current situation and future plans, and clarifying my values). Beta testing findings Fifteen women who had completed cancer treatment (mean age 41.33 ± 3.16 years, mean age at diagnosis 36.07 ± 3.91 years) participated in beta testing of the SHARE decision aid. Most participants had a history of breast cancer (93.3%), while one had leukemia. At diagnosis, 40.0% were Stage I, 33.3% Stage II, and 20.0% Stage III. Almost all underwent surgery (93.3%) and chemotherapy (100.0%); 80.0% received radiotherapy. Most participants were married at diagnosis (73.3%) and highly educated (80.0% ≥ college). Table 2 provides full details. Beta testing: value clarification results Participants rated “starting treatment as soon as possible” (mean 9.67, SD 0.72) and “focusing solely on cancer treatment” (mean 9.33, SD 0.98) as most important, followed by “minimizing financial burden” (mean 8.07, SD 1.91) and “avoiding physical burden” (mean 7.73, SD 2.22). Lower ratings were reported for “having a child in the future” (mean 6.33, SD 3.66) and “avoiding infertility” (mean 5.40, SD 3.42). Family opinions (mean 7.33, SD 2.61) and health care professionals’ recommendations (mean 7.87, SD 2.13) were rated at intermediate levels (Table 3). Beta testing: acceptability and usability Mean ratings of information presentation ranged from 2.73 to 3.40 on a four-point scale across the seven modules. Modules 3 (Exploring FP options) and 5 (Clarifying my values) received the highest ratings (3.40 and 3.33), whereas Modules 1 and 4 received the lowest (both 2.73). Most participants (66.7%) felt the information provided was adequate, 26.7% wanted more, and 6.7% felt it was too much. The content was perceived as balanced by 80.0% of participants, while 20.0% considered it somewhat favorable toward FP. Regarding usefulness, 73.3% indicated the tool helped with decision-making. Decision-facilitation feedback was positive across all modules, with at least two-thirds reporting that each step facilitated decision-making (Table 4). Beta testing: UEQ evaluation Among the six UEQ evaluation dimensions, Perspicuity received the highest score (mean 1.42, SD 0.88), followed by Efficiency (mean 0.98, SD 0.81) and Dependability (mean 0.97, SD 0.86). According to the standard UEQ interpretation, values between −0.8 and 0.8 indicate a neutral evaluation, values above 0.8 indicate a positive evaluation, and values below −0.8 indicate a negative evaluation. As illustrated in Fig. 4, Perspicuity, Efficiency, and Dependability were positively evaluated, whereas Attractiveness (mean 0.64, SD 0.82), Stimulation (mean 0.33, SD 0.87), and Novelty (mean −0.02, SD 0.92) fell within the neutral range. To strengthen interpretation, the observed scores were additionally compared with the established UEQ benchmark for web sites and web services. In this benchmark, Perspicuity was rated as above average, Efficiency was located at the threshold between the below-average and above-average ranges, and Attractiveness, Dependability, Stimulation, and Novelty fell within the below-average range. Overall, these findings indicate that SHARE performed relatively better in pragmatic quality dimensions than in hedonic quality dimensions, with clarity of use emerging as its strongest aspect.Fig. 4Mean User Experience Questionnaire (UEQ) scores across six dimensions among beta-testing participants (n = 15). Shaded bands with direct labels indicate the standard UEQ evaluation ranges, with dashed lines marking the −0.8 and 0.8 thresholds: scores above 0.8 denote a positive evaluation, scores between −0.8 and 0.8 a neutral evaluation, and scores below −0.8 a negative evaluation. Error bars represent 95% confidence intervals of the scale means, calculated as mean ± 1.96 × SD/√n (a normal-approximation 95% confidence interval, consistent with the CONFIDENCE function of the UEQ Data Analysis Tool). SD, standard deviation. Mean User Experience Questionnaire (UEQ) scores across six dimensions among beta-testing participants (n = 15). Shaded bands with direct labels indicate the standard UEQ evaluation ranges, with dashed lines marking the −0.8 and 0.8 thresholds: scores above 0.8 denote a positive evaluation, scores between −0.8 and 0.8 a neutral evaluation, and scores below −0.8 a negative evaluation. Error bars represent 95% confidence intervals of the scale means, calculated as mean ± 1.96 × SD/√n (a normal-approximation 95% confidence interval, consistent with the CONFIDENCE function of the UEQ Data Analysis Tool). SD, standard deviation. Discussion Main findings Reportedly, decision aids reduce decisional conflict, improve knowledge, and support value-congruent choices in oncology settings.17,22 Building on these findings, this study developed and pilot tested SHARE, a web-based decision aid that supports FP decision-making among women of reproductive age with cancer. SHARE was developed using a systematic process informed by the IPDAS and the ODSF, which provided theoretical grounding and structured guidance for its design.23,33 The ODSF provides a structured approach for identifying decisional needs, delivering appropriate decision support, and improving decisional outcomes. Consistent with this framework, SHARE addresses both cognitive and affective dimensions of decision-making by integrating clear evidence-based information, structured value clarification, and emotional reassurance. This multidimensional design was developed with reference to IPDAS 2021 guidance, which emphasizes not only factual accuracy and balanced information but also psychological support and value-congruent choice facilitation.23 Beta-testing findings demonstrated that participants rated timely initiation of cancer treatment more highly than fertility-related concerns, echoing prior work demonstrating that young women with cancer often value survival more highly than future childbearing.34 This finding highlights the central tension between survival and reproductive goals, which represents a critical challenge in clinical practice: how to present FP not as a competing priority, but as an integrated aspect of survivorship care. Although FP was recognized as desirable by some, participants emphasized that such interventions should not compromise oncologic treatment. Acceptability and usability evaluations further support SHARE's promise. Mean ratings of the seven modules ranged from 2.73 to 3.40 on a 4-point scale, and most participants (11 of 15, 73.3%) considered the program useful for decision-making—consistent with evaluations of similar decision aids, such as the Pathways website, which most users rated favorably,20 and a fertility-focused mobile application for men with a history of cancer.35 Importantly, 12 of 15 users (80.0%) perceived the content as balanced—a key IPDAS criterion,36 as perceived bias undermines user trust in patient decision support tools. Unlike previous decision aids developed primarily in Western contexts, SHARE incorporates sociocultural and system-level factors unique to South Korea's health care environment, including family involvement, limited consultation time, and hierarchical decision-making norms, which may enhance its contextual relevance and feasibility in future implementation. These findings align with other SDM FP interventions emphasizing cultural and contextual tailoring as determinants of effectiveness.16,20 From a human–computer interaction perspective, SHARE showed relatively stronger pragmatic than hedonic quality. In particular, Perspicuity was the most favorably rated UEQ dimension and was positioned in the above-average range of the established benchmark for web sites and web services, suggesting that users found the program relatively easy to understand and navigate. By contrast, the below-average benchmark positioning of Dependability, Attractiveness, Stimulation, and Novelty suggests a need to improve users’ perceived control and the predictability of interactions, as well as visual appeal and engagement (e.g., improved visual design and interactive storytelling); the Dependability rating should not be interpreted as a direct measure of software reliability. In this sample, pragmatic dimensions were rated more favorably than Stimulation and Novelty; this pattern may inform future design refinement.37,38 Implications for nursing practice and research Clinically, these findings have important implications. Despite guideline recommendations from ASCO emphasizing early fertility counseling,1 numerous patients continue to report inadequate discussions regarding reproductive risks and options.39 By providing structured evidence-based information in plain language and incorporating value clarification, SHARE offers a practical mechanism for facilitating conversations in time-limited oncology consultations. Similar interventions can reduce decisional conflict and regret,14,19 suggesting that SHARE may help facilitate onco-fertility counseling in future implementation studies. Limitations This study had several limitations. First, both the needs assessment and the beta test were conducted with cancer survivors whose retrospective perspectives may not fully capture the acute decisional conflict experienced at the point of diagnosis. Although the eligibility criteria did not restrict cancer type or sex, the beta test sample turned out to be predominantly composed of participants with a history of breast cancer (14 of 15, 93.3%), likely reflecting the fact that breast cancer is the most common malignancy in Korean women of reproductive age.40 Generalization to other cancer types should therefore be interpreted with caution, as cancer types differ in treatment timelines and fertility implications — for example, treatment timing is regimen- and patient-specific, and early referral may permit FP discussion without clinically meaningful delay in many patients with breast cancer,41 whereas patients with acute leukemia or aggressive lymphoma often initiate cytotoxic therapy within days and have minimal opportunity to weigh fertility considerations.42 This, combined with the small sample, restricts the study's generalizability. Furthermore, recruiting beta-testing participants through an online commercial research panel may have introduced selection bias, as such panels tend to overrepresent individuals with higher digital literacy and greater willingness to complete online surveys. In addition, SHARE was developed and tested within a single-country (South Korean) health care context; cross-cultural adaptation and multi-site evaluation are needed to assess transferability to other settings. Moreover, readability assessments (e.g., Flesch–Kincaid grade level) and update procedures, both of which are recommended by the IPDAS quality criteria, were not systematically evaluated. Future studies should prospectively evaluate SHARE in newly diagnosed patients across diverse oncology populations, including hematologic, gynecologic, and pediatric cancers, and incorporate iterative updates aligned with emerging clinical guidelines. In addition, decision-making outcomes such as decisional conflict and behavioral impact (e.g., actual FP choices and adherence) should be evaluated in subsequent efficacy trials. Furthermore, implementation research is warranted to explore how SHARE can be integrated into real-world oncology workflows through institutional endorsement, multidisciplinary coordination, and clinician training—consistent with implementation literature on shared decision making.43 Conclusions SHARE, a web-based decision aid for FP decisions among women of reproductive age with cancer in South Korea, was developed through a systematic, IPDAS- and ODSF-informed process. In a small post-treatment pilot, SHARE showed preliminary evidence of acceptability and stronger pragmatic than hedonic user-experience ratings; decisional and clinical effectiveness were not evaluated. Prospective evaluation in newly diagnosed women across diverse cancer types is warranted. CRediT authorship contribution statement Jeehee Han: Conceptualization, Funding acquisition, Methodology, Investigation, Writing – original draft, Writing – review & editing. Mina Jang: Conceptualization, Data curation, Formal analysis, Visualization. Seul Ki Kim: Validation, Writing – review & editing. Jinyoung Park: Conceptualization, Funding acquisition, Methodology, Writing – original draft, Writing – review & editing. All authors have read and approved the final manuscript. Ethics statement This study was conducted in two distinct phases, each receiving independent ethical approval from the Institutional Review Board (IRB) of Chung-Ang University. Phase 1 (needs assessment) was approved under IRB No. 1041078-202203-HR-101 on June 23, 2022, with a continuing review approved on December 8, 2023. Phase 2 (intervention development and testing) was approved under Approval No. 1041078-20240309-HR-047 on June 5, 2024. This study was conducted in accordance with the Declaration of Helsinki. All participants provided written informed consent. Data availability The data that support the findings of this study are available on request from the corresponding author, JP. The data are not publicly available due to ethical and privacy restrictions, as they contain sensitive participant information. Declaration of generative AI and AI-assisted technologies in the writing process During the preparation of this work the authors used Claude (Anthropic) to assist with language editing and figure preparation. The authors reviewed and edited the output as needed and take full responsibility for the content of the published article. Funding This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korean government (Ministry of Science and ICT) (Grant No. NRF-2021R1I1A1A01049292) and the Soonchunhyang University Research Fund (Grant No. 20251343). The funders had no role in the study design; data collection, analysis, or interpretation; preparation of the manuscript; or the decision to submit the article for publication. Declaration of competing interest The authors declare no conflict of interest.